|
|
|
|
|
|
|
|
Future Oncology, Future Medicine
December 2013
Today we have a much greater
understanding regarding which patients with ovarian cancer in particular
will benefit the most from treatment with trabectedin plus PLD:
Sections:
Manufacturing
difficulties resulted in a shortage of pegylated liposomal doxorubicin
(PLD), but these problems have recently been resolved and PLD is now
available again. It follows that oncologists now have access to this
important anticancer therapy and the combination of trabectedin
(Yondelis®, PharmaMar, Madrid, Spain) plus PLD can once more
be prescribed for the treatment of relapsed ovarian cancer, the topic
under discussion at this symposium.
▪ The first group involves patients with partially platinum-sensitive disease;
| |||||
▪ The
second group includes patients fully platinum-sensitive but who, for
whatever reason, cannot be retreated with platinum therapy.
|
These
are important clinical problems that oncologists have to deal with in
their daily practice and in this symposium we count on eminent experts
in the field to present some of the most recent data on these topics
under the chairmanship of Andres Poveda (Instituto Valenciano de
Oncología, Valencia, Spain) and Eric Pujade-Lauraine (Hôpital
Hôtel-Dieu, París, France). Key speakers at the symposium are Nicoletta
Colombo (European Institute of Oncology, University of Milan, Bicocca,
Milan, Italy), Maurizio D‘Incalci (IRCCS – Istituto di Ricerche
Farmacologiche Mario Negri, Milan, Italy), Antonio González (MD Anderson
Cancer Center, Madrid, Spain) and Isabel Ray-Coquard (Centre Léon
Bérard, Lyon, France). To discuss the findings that are presented with
the goal of providing an overall perspective we have the following
experts: Jalid Sehouli (European Competence Center for Ovarian Cancer,
Charité University Hospital, Berlin, Germany), Josep M del Campo (Vall
d‘Hebron University Hospital, Barcelona, Spain) and Domenica Lorusso
(Fondazione `IRCCS‘ National Cancer Institute, Milan, Italy).
Users who read this article also read:
Optimizing treatment of the partially platinum-sensitive ovarian cancer patient
Nicoletta Colombo
Summary | Full Text | PDF (493 KB) | PDF Plus(494 KB)
|
Add to Favorites
| Related
|
Reprints & Permissions
|
Increasing the chances for platinum-sensitive ovarian cancer patients
Antonio González
Summary | Full Text | PDF (946 KB) | PDF Plus(947 KB)
|
Add to Favorites
| Related
|
Reprints & Permissions
|
Trabectedin mechanism of action: what’s new?
Maurizio D’Incalci
Summary | Full Text | PDF (1476 KB) | PDF Plus(1477 KB)
|
Add to Favorites
| Related
|
Reprints & Permissions
|
Discussion: session 1 (requires subscription)
Jalid Sehouli, Josep M del Campo, Domenica Lorusso
Citation | Full Text | PDF (367 KB) | PDF Plus(367 KB)
|
Add to Favorites
| Related
|
Reprints & Permissions
What are the benefits of extending the platinum-free interval?
What is the importance of the sequence of treatment?
|
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.